View Larger Image
The conflict between genetic diagnostic test makers eager to recoup development costs through patent protection and patient groups seeking broader access to the tests resurfaced during the first of two hearings required by the patent law overhaul enacted in September. The hearing was held by the U.S. Patent and Trademark Office (USPTO) and is required to study how to ensure availability of confirming genetic diagnostic tests where gene patents and exclusive licensing for such tests exist. The final report is due June 16. Industry advocates oppose government efforts to force them to ensure independent second opinion genetic diagnostic testing, calling that an unlawful infringement of their patents. Patient advocates oppose the patenting of genes and genetic diagnostic tests, saying the resulting patent monopolies harm patients.
MORE RELATED GEN NEWS HIGHLIGHTS
MORE RELATED INSIGHT & INTELLIGENCE™
MORE RELATED GEN ARTICLES
Will you be voting for any of the candidates on GEN’s Hall of Shame list in the next election?
Be sure to add update@genengnewsemail.com to your Address Book or Safe Senders List.
Click here for instructions.
If you have any questions about your subscription, click here to email us or call at (914) 740-2189.
You may also be interested in subscribing to the GEN magazine, an indispensable resource for everyone involved in the business of translating discoveries at the bench into solutions that fight disease and improve health, agriculture, and the environment. Subscribe today to see why over 60,000 biotech professionals read GEN to keep current in the areas of genomics, proteomics, drug discovery, biomarker discovery, bioprocessing, molecular diagnostics, collaborations, biotech business trends, and more.
© 2013 Genetic Engineering & Biotechnology News All Rights Reserved